肝细胞癌免疫治疗生物标志物的研究进展

摘要/Abstract

摘要： 肝细胞癌是最常见的恶性肿瘤之一。由于起病隐匿,大约一半的患者确诊时已中晚期。2007年靶向治疗开始成为晚期肝细胞癌一线治疗,近年来免疫治疗在肝细胞癌中的作用越来越重要,尤其是靶免联合治疗取得了明显的疗效。但免疫治疗在肝细胞癌中的疗效差异较大,寻找免疫治疗疗效预测相关的生物标志物尤为重要。目前尚未有达成共识的肝细胞癌免疫生物标志物,本文就肝细胞癌免疫治疗生物标志物的研究进展进行综述。

黄孙桦, 刘建东, 黄罡. 肝细胞癌免疫治疗生物标志物的研究进展[J]. 肝脏, 2023, 28(5): 510-512.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021,71(3): 209-249.
[2] Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet,2022,400(10360): 1345-1362.
[3] Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016. JNCC, 2022. 2(1): 1-9.
[4] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国抗癌协会肝癌专业委员会,北京医学会外科学分会肝脏学组,中华肝胆外科杂志编辑委员会. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021 版). 肝癌电子杂志, 2021,8(2):6-15.
[5] Park JW, Chen M, Colombo M, et al., Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int, 2015,35(9):2155-2166.
[6] Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet, 2018. 391(10127): 1301-1314.
[7] Bruix J, Sherman M, Llovet JM, et al. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol, 2001,35(3):421-430.
[8] Zhou J, Sun H, Wang Z, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 2020,9(6):,682-720.
[9] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018. 69(1):182-236.
[10] Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Front Immunol, 2020, 11: 940.
[11] Wang Y, Tong Z, Zhang W, et al. FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. Front Oncol, 2021,11: 683419.
[12] Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther, 2015,14(4):847-856.
[13] Zhu J, Zhang T, Li J, et al. Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. Front Pharmacol,2019,10:673.
[14] Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res,2008,18(1): 85-98.
[15] Xing X, Guo J, Ding G, et al. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology, 2018,7(3): e1356144.
[16] Losic B, Craig AJ, Villacorta-Martin C, et al. Intratumoral heterogeneity and clonal evolution in liver cancer. Nat Commun, 2020,11(1): 291.
[17] Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 2017,153(3):812-826.
[18] Berraondo P, Ochoa MC, Olivera I, et al. Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by beta-Catenin Activation. Cancer Discov, 2019,9(8):1003-1005.
[19] Haber PK, Castet F, Torres-Martin M, et al. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology,2023,164(1):72-88, e18.
[20] Mazzocca A, Giannelli G, Antonaci S. Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link? Biochim Biophys Acta, 2010,1806(1): 74-81.
[21] Oh S, Park Y, Lee HJ, et al. A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy. Cancers (Basel), 2020,12(3):745.
[22] Zhu L, Zhao Y, Yu L, et al. Overexpression of ADAM9 decreases radiosensitivity of hepatocellular carcinoma cell by activating autophagy. Bioengineered, 2021,12(1):5516-5528.
[23] 蒋礼青, 文献计量学结合主题建模及生物信息学分析:肝癌免疫治疗的进展和新型标记物研究. 中国医科大学,2022.
[24] Feun LG, Li YY, Wu C, et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer, 2019,125(20): 3603-3614.
[25] Hopkins AC, Yarchoan M, Durham JN, et al. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI Insight, 2018. 3(13):e122092.
[26] Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017,545(7652): 60-65.
[27] Nakaya A, Kurata T, Yoshioka H, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol, 2018,23(4): 634-640.
[28] Wu X, Li J, Gassa A, et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci, 2020,16(9): 1551-1562.
[29] Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 2019,20(2): 282-296.
[30] Chen Y, Wang Q, Shi B, et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine, 2011,56(2): 231-238.
[31] Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018,67(1):358-380.
[32] Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol, 2017,14(9): 527-539.
[33] Zhou A, Tang L, Zeng S, et al. Gut microbiota: A new piece in understanding hepatocarcinogenesis. Cancer Lett, 2020, 474: 15-22.